The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 2, 2002, Pages 131-137

  Freeman, L M ^a   Krynyckyi, B R ^a   Li, Y ^a   Korupulu, G ^a   Saleemi, K ^a   Haseman, M K ^a   Kahn, D ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Antibodies, monoclonal; Lymph nodes, radionuclide imaging; Prostatic neoplasms, diagnosis; Prostatic neoplasms, radionuclide imaging

Indexed keywords

CAPROMAB PENDETIDE IN 111; GLYCOPROTEIN; HORMONE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOPSY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSEMINATED CANCER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMAGING; IMMUNOSCINTIGRAPHY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; METASTASIS; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE SURGERY; RECURRENT CANCER; SALVAGE THERAPY;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; FALSE POSITIVE REACTIONS; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS;

EID: 0036620678     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cancer statistics, 2001
2. The accuracy of staging carcinoma of the prostate
3. Staging of prostate cancer: Results of radiology diagnostic oncology group project comparison to three MR imaging techniques
4. 111In Capromab Pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostectomy
5. The detection of metastatic prostate cancer with simultaneous dual isotope SPECT images
6. 111In Capromab Pendetide immunoscintigraphy to predict lymph node involvement in high-risk prostate cancer patients
7. 111In Capromab Pendetide: Evaluation before definitive therapy in patients with prostate cancer
8. The dual-isotope ProstaScint imaging procedure: Clinical experience and staging results in 145 patients
9. Follow-up Prostascint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy
10. Multicenter ProstaScint imaging results in 2154 patients with prostate cancer
11. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation
12. Two different lymph node metastatic patterns of a prostate cancer
13. Metastases from cancer of the prostate
14. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
15. 111In labeled Capromab Pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
16. 111In Capromab Pendetide MAb Scan to predict radiotherapy response of tumor recurrence following radical prostatectomy: Long-term follow-up
17. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues
18. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
19. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies
20. Prostate specific membrane antigen expression in normal and malignant human tissue
21. ProstaScint: An update